ArticleHuman vaccines & immunotherapeutics2025
The influence of SARS-CoV-2 vaccination on in vitro fertilization outcomes.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In December 2020, the FDA granted emergency use approval for 2 separate mRNA vaccines to combat the COVID-19 pandemic. While many questions as to the long-term safety of the vaccine were raised, this was particularly acute for those patients trying to conceive and among those utilizing assisted reproductive technologies. The study aimed to assess the effect of recent mRNA SARS-CoV-2 vaccination on IVF cycle outcomes. A retrospective case-control study, including all IVF patients under the age of 40 years in a hospital-based practice from January 1 to May 31, 2021. The study group included patients who received two doses of the Pfizer/BioNTech vaccine BNT162b2 SARS-COV-2 vaccine between 7 days to 6 months prior to starting IVF. The control group included unvaccinated patients from the same time period in the same year and in 3 previous years. IVF cycle results were compared between the groups. Three hundred and eighty-five women met the inclusion criteria; 349 in the control group and 36 in the vaccinated group. Demographic and clinical characteristics were comparable between the groups. The pregnancy rate was 33.3% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.